Nanobiotix S.A. (NBTX)


+0.23 (+2.79%)
Symbol NBTX
Price $8.47
Beta 1.280
Volume Avg. 0.25M
Market Cap 314.161M
Shares () -
52 Week Range 1.75-11.0
1y Target Est -
DCF Unlevered NBTX DCF ->
DCF Levered NBTX LDCF ->
ROE 44739.61% Strong Buy
ROA -95.44% Strong Sell
Operating Margin -
Debt / Equity -196.59% Sell
P/E -4.92 Strong Sell
P/B -10.27 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest NBTX news

Mr. Laurent Levy Ph.D.
NASDAQ Global Select

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.